ABSTRACT
HIGHER SERUM URIC ACID LEVELS IN MULTIPLE SCLEROSIS PATIENTS AFTER LONGTERM INTERFERON BETA TREATMENT
. There were no patients with chronic renal disease or diabetes mellitus, nor were there any receiving acetylsalicylic acid and thiazide diuretics. In Clinical Center Kragujevac, the normal range of serum uric acid levels was 150 to 350 μmol/l for females and 210 to 420 μmol/l for males. All MS patients consented to be involved in the study. The local Ethical Committee approved this investigation.
The clinical and demographic characteristics of the MS patients are presented in Table 1 .
The SYSTAT program was used for statistical analysis. Significant differences between groups was calculated by the Wilcoxon Mann-Whitney U test. Differences in mean values were calculated using t-test. Correlations were analysed using Spearman's rank correlation. The results are given as mean ± SD.
RESULTS
Serum uric acid levels before and after treatments with interferon beta (i.e., the follow-up period) are pre-
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) with unknown aetiology. In recent years, there have been advances in understanding the pathogenesis of MS. There is significant evidence that oxidative stress is involved in MS pathology (1, 2) . The proximal agents of neuronal cell damage might be nitric oxide and peroxynitrate (forming in a reaction between nitric oxide and superoxide anion radicals), which can compromise antioxidant defences and cause oxidative damage to tissues (3, 4) . Uric acid is an important physiological antioxidant in the total antioxidant capacity of blood plasma (5, 6, 7). There is some evidence that MS patients have lower serum uric acid levels (8, 9, 10, 11, 12, 13, 14) and that MS and gout (chronic hyperuricaemia) are mutually exclusive diagnoses (15, 16) .
Interferon beta is an efficacious and safe first line treatment for relapsing MS. It is the first therapeutic intervention demonstrated to modify the natural history of MS (reduces the relapse rate, decreases radiological disease activity, and slows progression of MS). Interferon beta has a range of effects on the immune system, which could explain its positive effects on MS (17, 18, 19, 20) .
The aim of this study is to estimate changes in serum uric acid levels before and after long-term interferon beta treatment. The inclusion criteria for treatment included being over 18 years of age, having had at least two relapses in last two years, and having an EDSS score (Expanded Disability Status Scale score) (22) of less than or equal to 3.5 (criteria for including MS patients receiving interferon beta treatment in Serbia). During this seven-year period, 26 patients stopped the treatment (16 interferon beta 1a and 10 interferon beta 1b patients). We investigated the serum uric acid levels of the MS patients before initiating the treatment and at the end of the treatment (in cases of treatment discontinuation) or in January 2011 for the patients who continued the treatment.
MATERIALS AND METHODS

Serum
All blood samples were taken as part of a routine laboratory screening for interferon beta treatment (looking for possible adverse events every six months or at the end of the treatment). Serum uric acid levels were measured using a quantitative enzymatic assay (Elitech Diagnostic, Table 2 . The MS patients were found to have significantly higher mean serum uric acid levels after a mean of 3,9 years of interferon beta treatment compared with pretreatment serum uric acid levels (272,31±78,21 μmol/l vs. 210,17±53,65 μmol/l; p=0,019, Wilcoxon Mann-Whitney U-test). On the other hand, there were no significant differences in serum uric acid levels in MS patients after treatment with interferon beta 1b and interferon beta 1a (281,33±52,28 μmol/l vs. 269,89±93,71 μmol/l, respectively; Wilcoxon Mann-Whitney U-test, p=0,298). Pretreatment serum uric acid levels increased in 88 patients, decreased in five patients and were unchanged in eight patients after a mean 3,9 years of treatment. We also found a significant linear correlation between the duration of interferon beta treatment and changes (increasing) in serum uric acid levels (p=0,021).
DISCUSSION
Interferon beta is a well-established and safe first line treatment for MS. To our knowledge, this is the first study to compare changes in serum uric acid levels before and after long-term interferon beta treatment. We previously reported higher uric acid levels after one year of interferon beta 1b treatment in a small preliminary sample of patients (24) .
Several studies have demonstrated lower serum uric acid levels in MS patients and suggest that higher levels of uric acid may offer protection against the development of MS (5-16). There are some opinions that the lower urate levels among multiple sclerosis cases could be a consequence rather than a cause of the disease (25) . Consequently, treatment attempts in human MS with a precursor of uric acid have been reported (26, 27) . A few studies have demonstrated elevated serum uric acid levels after the administration of some drugs, such as glatiramer acetate (28) and high-dose methylprednisolone (29) , indicating that some beneficial effects of these drugs might be due to the elevation of serum uric acid levels.
Interferon beta reduces the exacerbation rate in patients with relapsing remitting (RR) MS, decreases disease activity in the brain (measured as the identification of new or enlarging lesions in serial brain magnetic resonance imaging (MRI)), and slows the progression of MS. Interferon beta exerts a large range of effects on the immune system, which can explain its positive effects on MS, including antagonism of the proinflammatory cytokine interferon gamma (17, 18) , inhibition of the production of chemokines and matrix metalloproteinases (19) , and increased production of Interleukin 10 (20) .
The results of this study indicate that one of the beneficial effects of interferon beta might be based on the elevation of serum levels of uric acid as a natural scavenger of peroxynitrite.
